Ensayos clínicos - Hematología oncología pediátrica en Minnesota - Centro Pediátrico de Mayo Clinic
COVID-19 consejos información actualizada y opciones de vacunas
Infórmate sobre la COVID-19 y las vacunas contra esta enfermedad, y conoce las novedades para pacientes y visitantes de Mayo Clinic. Para navegación del sitio Para acceso a contenido Este contenido no tiene una versión en inglés Este contenido no tiene una versión en árabe Departamentos y centros Hematología oncología pediátrica
Clinical Trials
A continuación, se enumeran los ensayos clínicos actuales.
28 estudios en Hematología oncología pediátrica en Minnesota
(solo estudios abiertos). Filtra esta lista de estudios por sede, estatus, etc. A Study to Evaluate Performance of Coagulation Laboratory Testing in Children and Young Adults
Rochester, Minn. The primary purpose of this study is to generate pediatric-specific reference ranges that take into account patient sex, age, corrected gestational age, ethnicity, etc., and laboratory variables for various coagulation studies. A Study to Identify Late-Occurring Complications in Childhood Cancer Survivors
Rochester, Minn. The purpose of this trial is to identify cancer survivors who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer. A patient's genes may affect the risk of developing complications, such as congestive heart failure, heart attack, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications. A Study of Ovarian Tissue Freezing for the Preservation of Fertility in Children
Rochester, Minn. The purpose of this study is to offer ovarian tissue cryopreservation to female pediatric patients (birth-17 years of age) with fertility threatening medical diagnoses or facing surgery, chemotherapy or radiation therapy that may cause loss of reproductive potential. Since this procedure is currently considered experimental, the establishment of an IRB protocol under which this opportunity can be offered is needed. A Study to Predict Response to Virotherapy and Immunotherapy by Using an Ex-Vivo Three-Dimensional Patient-Derived Organoid Model of Pediatric Urological Cancers
Rochester, Minn. The purpose of this study is threefold: the first aim is to use patient-derived fresh tumor tissue to create cell lines and 3D tumor models (i.e. organoids) that preserve the characteristics of the original tumor. The preservation of the original tumor's drug resistance/response profile will be a major focus of this aim. The second aim is to conduct high-throughput testing of various drugs (e.g., virotherapy, immunotherapy) on these cell lines and 3D tumor models. The completion of the second aim is an important step towards developing a platform that can help guide treatment decisions for future patients, based on the drug response observed in the cell lines and 3D tumor models. The third aim is to use pan-omics approaches (i.e., genomics, proteomics, metabolomics) to find markers of drug response based on the results of the high-throughput drug testing on the cell lines and 3D tumor models. ATHN 9 Severe Von Willebrand Disease Natural History Study
Rochester, Minn. The purpose of this study is to assess the safety of various Von Willebrand Factor (VWF) regimens for different indications (on-demand, surgery and prophylaxis) in adult and pediatric participants with clinically severe congenital VWD. A Study of the Drugs Selumetinib Versus Carboplatin Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
Rochester, Minn. The pupose of this study is to evaluate whether or not selumetinib works just as well as the standard treatment with carboplatine/vincristine (CV) for subjects with NF1-associated low grade glioma (LGG), and to see if selumetinib is better than CV in improving vision in subjects with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that low grade glioma tumor cells need for their growth. This results in killing tumor cells. Drugs used as chemotherapy, such as carboplatin and vincristine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether selumetinib works better in treating patients with NF1-associated low-grade glioma compared to standard therapy with carboplatin and vincristine. Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphomas or Histiocytic Disorder
Rochester, Minn. The purpose of this Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas. Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
Rochester, Minn. This randomized phase III trial studies how well combination chemotherapy (vincristine sulfate, dactinomycin, cyclophosphamide alternated with vincristine sulfate and irinotecan hydrochloride) works compared to combination chemotherapy plus temsirolimus in treating patients with rhabdomyosarcoma (cancer that forms in the soft tissues, such as muscle), and has an intermediate chance of coming back after treatment (intermediate risk). Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Combination chemotherapy and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy or combination chemotherapy plus temsirolimus is more effective in treating patients with intermediate-risk rhabdomyosarcoma. A Study of Heated Intra-peritoneal Chemotherapy H I P E C with Doxorubicin and Cisplatin in Pediatric Patients with Pelvic and Abdominal Rhabdomyosarcoma
Rochester, Minn. The primary purpose of this study is to assess the feasibility of heated intra-peritoneal chemotherapy (HIPEC) with doxorubicin (DOXO) and Cisplatin (CDDP) after surgical resection of pediatric pelvic and abdominal tumors, and to assess morbidity, hospital length of stay and peri-operative mortality outcomes for pediatric patients with intraperitoneal sarcoma undergoing hyperthermic intraperitoneal chemotherapy. A Study to Evaluate Bleomycin Carboplatin Etoposide or Cisplatin in Treating Pediatric and Adult Patients with Germ Cell Tumors
Rochester, Minn. The purpose of this study is to evaluate how well bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and adult patients with germ cell tumors. Active surveillance may help doctors to monitor subjects with low risk germ cell tumors after their tumor is removed. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Otros temas en atención en Mayo Clinic
Consultas Ubicación Guía para pacientes y visitantes Servicios internacionales Departamentos y centros médicos Doctores y personal médico Servicios en línea para pacientes Facturación y seguros Ensayos clínicos Colaboraciones comerciales internacionales Información sobre Mayo Clinic Contáctenos . Departamentos y centros Children’s Center (Centro Pediátrico) Hematología oncología pediátrica Ensayos clínicos Mayo Clinic Footer
Para consultasPara donarContáctanosMayo Clinic: InformaciónEmpleadosMapa del sitioSobre el sitio Legal Conditions and Terms
Cualquier uso de este sitio constituye su acuerdo con los términos y condiciones y política de privacidad para los que hay enlaces abajo. Términos y condiciones Política de privacidad Aviso de prácticas en cuanto a privacidad Para administrar cookies Advertising
Mayo Clinic es una organización sin fines de lucro, y el dinero recaudado con la publicidad en Internet apoya nuestra misión. Mayo Clinic no respalda ningún producto ni servicios de terceros que se anuncien.Política sobre publicidad y promociónOportunidades para publicidad y promoción Reprint Permissions
Se puede reimprimir una sola copia de estos materiales para usar en forma personal y no comercial. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," y el triple escudo que es el logotipo de Mayo Clinic son marcas registradas de Mayo Foundation for Medical Education and Research. 1998-2022 Mayo Foundation for Medical Education and Research (MFMER). All rights reserved.